AzurRx BioPharma Inc (NASDAQ:AZRX) saw a significant increase in short interest during the month of September. As of September 30th, there was short interest totalling 457,800 shares, an increase of 206.2% from the August 30th total of 149,500 shares. Based on an average daily trading volume, of 332,400 shares, the days-to-cover ratio is presently 1.4 days. Approximately 2.2% of the company’s stock are short sold.
Hedge funds have recently made changes to their positions in the company. Royal Bank of Canada acquired a new position in shares of AzurRx BioPharma in the second quarter valued at about $48,000. JPMorgan Chase & Co. acquired a new stake in AzurRx BioPharma during the second quarter worth about $57,000. BlackRock Inc. grew its holdings in AzurRx BioPharma by 57.6% during the second quarter. BlackRock Inc. now owns 42,313 shares of the company’s stock worth $72,000 after acquiring an additional 15,463 shares during the period. Finally, Vanguard Group Inc. grew its holdings in AzurRx BioPharma by 255.0% during the second quarter. Vanguard Group Inc. now owns 260,306 shares of the company’s stock worth $443,000 after acquiring an additional 186,985 shares during the period. 12.12% of the stock is currently owned by institutional investors and hedge funds.
A number of equities research analysts have commented on the company. ValuEngine upgraded AzurRx BioPharma from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. HC Wainwright decreased their price target on AzurRx BioPharma from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, September 26th. Seven equities research analysts have rated the stock with a buy rating, AzurRx BioPharma currently has a consensus rating of “Buy” and an average target price of $7.25.
AzurRx BioPharma (NASDAQ:AZRX) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.03). Research analysts anticipate that AzurRx BioPharma will post -0.76 EPS for the current year.
About AzurRx BioPharma
AzurRx BioPharma, Inc researches and develops non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product pipeline consists of two therapeutic proteins under development, including MS1819, a yeast derived recombinant lipase, which is in Phase II clinical trial for the treatment of exocrine pancreatic insufficiency associated with chronic pancreatitis and cystic fibrosis; and AZX1101, an enzymatic combination of bacterial origin for the prevention of hospital-acquired infections and antibiotic-associated diarrhea.
See Also: What is a recession?
Receive News & Ratings for AzurRx BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AzurRx BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.